Original Research Article
Serum Folate Levels and Subsequent Adverse Cerebrovascular Outcomes in Elderly PersonsMaxwell C.J.a,b · Hogan D.B.a-c · Ebly E.M.c
Departments of aCommunity Health Sciences, bMedicine, and cClinical Neurosciences, University of Calgary, Alta, Canada
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Recent epidemiologic studies have shown an association between low serum folate levels and risk of vascular disease, including stroke and various types of vascular cognitive impairment. We examined data from the Canadian Study of Health and Aging (CSHA), a population-based, prospective 5-year investigation of the epidemiology of dementia among Canadians aged 65+ years. The risk of an adverse cerebrovascular event (including vascular dementia, vascular cognitive impairment, or fatal stroke) during follow-up, was assessed according to serum folate quartiles among subjects with no evidence of dementia at baseline (n = 369). After adjusting for certain covariates, including cardiovascular disease and nutritional indices, education, smoking and baseline cognitive status, the risk estimate for an adverse cerebrovascular event associated with the lowest folate quartile compared with the highest quartile was OR 2.42 (95% CI 1.04–5.61). Results from stratified analyses also showed that relatively low serum folate was associated with a significantly higher risk of an adverse cerebrovascular event among female (OR 4.02, 95% CI 1.37–11.81) but not male (OR 1.02, 95% CI 0.25–4.13) subjects. Among the total sample, there was a consistent trend toward poorer health and cognitive outcomes during follow-up (including mortality, cognitive decline and dementia) among those in the lowest folate quartile compared with the highest quartile. Low serum folate levels are independently associated with a significantly higher risk of an adverse cerebrovascular event, including vascular dementia and stroke death, among older, cognitively vulnerable persons.
© 2002 S. Karger AG, Basel
- Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057.
- Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S: Homocysteine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363–375.
- Kark JD, Selhub J, Adler B, Gofin J, Abramson JH, Friedman G, Rosenberg IH: Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999;131:321–330.
- Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D’Agostino RB, Wolf PA, Jacques PF, Wilson PWF: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077–1080.
- Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D’Agostino RB, Wilson PWF, Wolf PA: Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham study. Ann Intern Med 1999;131:352–355.
- Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–1050.
- Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ: A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924–1930.
- Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ: Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997;79:799–801.
- Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994;106:9–19.
- Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH: Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947–1953.
- Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204–210.
- Christen WG, Ajani UA, Glynn RJ, Hennekens CH: Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual? Arch Intern Med 2000;160:422–434.
- Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–2698.
- Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson CL: Serum total homocysteine concentrations in the Third National Health and Nutrition Examination Survey (1991–1994): Population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131:331–339.
- Kelly GS: Folates: Supplemental forms and therapeutic applications. Altern Med Rev 1998;3:208–220.
- Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH: Metabolic evidence that deficiencies of vitamin B12 (cobalamin), folate and vitamin B6 occur commonly in elderly people. Am J Clin Nutr 1993;58:468–476.
- Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J: Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85–89.
- Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ: A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:136–143.
- Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML: Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 1995;26:1166–1170.
- Morrison HI, Schaubel D, Desmeules M, Wigle DT: Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893–1896.
- Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359–364.
- Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC: Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12 and folate. Am J Epidemiol 1996;143:845–859.
- Robinson K, Arheart K, Refsum H, Brattström L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I, for the European COMAC Group: Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998;97:437–443.
- Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer’s disease. Arch Neurol 1998;55:1449–1455.
- Wang HX, Wahlin Å, Basun H, Fastbom J, Winblad B, Fratiglioni L: Vitamin B12 and folate in relation to the development of Alzheimer’s disease. Neurology 2001;56:1188–1194.
- Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997;349:151–154.
- Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR: Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: Findings from the Nun Study. Am J Clin Nutr 2000;71:993–998.
- Ebly EM, Schaefer JP, Campbell NRC, Hogan DB: Folate status, vascular disease and cognition in elderly Canadians. Age Ageing 1998;27:485–491.
- Clarke R, Frost C, Leroy V, Collins R: Lowering blood homocysteine with folic acid-based supplements: Meta-analysis of randomized trials. Homocysteine Lowering Trialists’ Collaboration. BMJ 1998;316:894–898.
- Keane EM, O’Broin S, Kelleher B, Coakley D, Walsh JB: Use of folic acid-fortified milk in the elderly population. Gerontology 1998;44:336–339.
- Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314–318.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3 rev. Washington, American Psychiatric Association, 1987, pp 133–136.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
International Classification of Diseases, 10th revision. Categories F00–F99, mental, behavioural and developmental disorders (1987 draft of chapter V); in Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1987, Rep No MNH/MEP/87.1 rev 1.
- Canadian Study of Health and Aging Working Group: Canadian Study of Health and Aging: Study methods and prevalence of dementia. CMAJ 1994;150:899–913.
- Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RWR, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975;32:632–637.
- Moroney JT, Bagiella E, Desmond DW, Hachinski VC, Mölsä PK, Gustafson L, Brun A, Fischer P, Erkinjuntti T, Rosen W, Paik MC, Tatemichi TK: Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997;49:1096–1105.
- Rockwood K, Ebly E, Hachinski V, Hogan D: Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997;54:33–39.
- Maxwell CJ, Hogan DB, Ebly EM: Calcium-channel blockers and cognitive function in elderly people: Results from the Canadian Study of Health and Aging. CMAJ 1999;161:501–506.
Kelsey JL, Whittemore AS, Evans AS, Thompson WD: Methods in Observational Epidemiology, ed 2. New York, Oxford University Press, 1996.
SAS Institute Inc: SAS User’s Guide, Release 7.0 for Windows®. Cary, SAS Institute Inc, 1998.
- Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J: Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits. Am J Clin Nutr 1996;64:587–593.
- Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395–1398.
- Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D: Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895–1901.
- Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JCM, Koudstaal PJ, Grobbee DE: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam study. Arch Intern Med 1999;159:38–44.
- Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MMB: Total homocysteine and cognitive decline in a community-based sample of elderly subjects. The Rotterdam Study. Am J Epidemiol 1999;150:283–289.
- Nilsson K, Gustafson L, Faldt R, Andersson A, Brattstrom L, Lindgren A, Israelsson B, Hultberg B: Hyperhomocysteinemia: A common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853–859.
Joosten E, Lesaffre E, Riezler R, Ghekiere V, Dereymaeker L, Pelemans W, Dejaeger E: Is metabolic evidence for vitamin B12 and folate deficiency more frequent in elderly patients with Alzheimer’s disease? J Gerontol 1997;52:M76–M79.
- McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriat Psychiatry 1998;13:235–239.
- Riggs KM, Spiro A, Tucker K, Rush D: Relations of vitamin B12, vitamin B6, folate and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306–314.
- Hutto BR: Folate and cobalamin in psychiatric illness. Compr Psychiatry 1997;38:305–314.
- Bottiglieri T: Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev 1996;54:382–390.
- Diaz-Arrastia R: Hyperhomocysteinemia – A new risk factor for Alzheimer disease? Arch Neurol 1998;55:1407–1408.
- Graham I: Homocysteine in health and disease (editorial). Ann Intern Med 1999;131:387–388.
- Lipton SA, Kim WK, Choi YB, Kumar S, D’Emilia DM, Rayudu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923–5928.
- Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ: 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237–241.
- Bottiglieri T, Hyland K, Reynolds EH: The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137–152.
- Rozen R: Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996;19:171–178.
- Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096–1098.
- Webster SGP, Leerning JT: Erythrocyte folate levels in the young and old. J Am Geriatr Soc 1979;27:451–454.
- Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449–1454.
- Clarke R, Collins R: Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998;5:249–255.
- Vermeulen EGJ, Stehouver CDA, Twisk JWR, van den Berg M, de Jong SC, Mackaay AJC, van Campen CMC, Visser FC, Jakobs CAJM, Bulterijs EJ, Rauwerda JA: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial. Lancet 2000;355:517–522.
- Campbell NR: How safe are folic acid supplements? Arch Intern Med 1996;156:1638–1644.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.